// App-Quantinova.ai

TCT-452 : Two Biodegradable Polymer-Based Sirolimus-Eluting Stents with Differing Elution and Absorption Kinetics: Two-Year Outcomes of the PANDA III Trial

Researchers

Presenter

  • Changdong Guan

Principal Investigators

  • Bo Xu

  • Runlin Gao

Medical Centers

  • Fu Wai Hospital, National Center for Cardiovascular Diseases, China, Beijing, China

  • Fu Wai Hospital, Beijing, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Myocardial infarction

  • Venous thrombosis

  • Coronary Artery Disease

  • Diabetes

  • Spastic paraplegia, intellectual disability, nystagmus, and obesity

Biomarkers

  • PANDAR

Drug/Treatment

  • sirolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved